Agnes Loeb
Overview
Explore the profile of Agnes Loeb including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zago A, Aline A, Obongo-Anga F, Loeb A, Merle V, Vermeulin T
Eur J Surg Oncol
. 2025 Feb;
51(6):109634.
PMID: 40009929
Background: In many countries where hospitals are funded by a prospective payment scheme based on Diagnosis Related Groups (DRG), two risks may arise whenever legitimate extra costs are not considered:...
2.
Courtinard C, Gourgou S, Jacot W, Carton M, Guerin O, Vacher L, et al.
BMC Med
. 2023 Mar;
21(1):87.
PMID: 36882736
Background: Overall survival (OS) is the gold standard endpoint to assess treatment efficacy in cancer clinical trials. In metastatic breast cancer (mBC), progression-free survival (PFS) is commonly used as an...
3.
Cabel L, Carton M, Pistilli B, Dalenc F, Vanlemnens L, Levy C, et al.
Breast
. 2021 Feb;
56:18-25.
PMID: 33561617
Purpose: Among metastatic breast cancer (MBC) patients, those with a triple-negative breast cancer phenotype (mTNBC) have the worst prognosis, but the benefit of chemotherapy beyond second line on outcome remains...
4.
Lambertini M, Olympios N, Lequesne J, Calbrix C, Fontanilles M, Loeb A, et al.
Front Oncol
. 2019 Jul;
9:575.
PMID: 31355134
Limited evidence exists on the impact of adding a taxane, using endocrine therapy and carrying a deleterious germline mutation on ovarian reserve measured by anti-müllerian hormone (AMH) levels of young...
5.
Perol D, Robain M, Arveux P, Mathoulin-Pelissier S, Chamorey E, Asselain B, et al.
BMJ Open
. 2019 Feb;
9(2):e023568.
PMID: 30796119
Purpose: The currently ongoing Epidemiological Strategy and Medical Economics (ESME) research programme aims at centralising real-life data on oncology care for epidemiological research purposes. We draw on results from the...
6.
Bastit V, Bon-Mardion N, Picquenot J, Rainville V, Moldovan C, Francois A, et al.
Eur Arch Otorhinolaryngol
. 2018 Dec;
276(2):541-550.
PMID: 30523411
Objectives: To evaluate the benefit of cetuximab (Cx) addition to platinum-based and 5-fluorouracil chemotherapy (PFU) in unselected recurrent and/or metastatic head and neck cancer patients (R/MHNC) according to KRAS-LCS6 variant...
7.
Vermeulin T, Lucas M, Marini H, Di Fiore F, Loeb A, Lottin M, et al.
Bull Cancer
. 2018 Oct;
105(11):1003-1011.
PMID: 30322697
Introduction: During the last decade, most studies on totally implanted venous access-associated adverse events (TIVA-AE) were conducted retrospectively and/or were based on a limited sample size. The aim of our...
8.
Perdrix A, Saint-Ghislain M, Degremont M, David M, Khaznadar Z, Loeb A, et al.
Reprod Biomed Online
. 2017 Jun;
35(4):468-474.
PMID: 28652099
The impact of chemotherapy on fertility appears to be of essential importance for the youngest cancer survivors. The aim of this study was to assess plasma anti-Mullërian hormone (AMH) evolution,...
9.
Merle V, Marini H, Di Fiore F, Lottin M, Gray C, Loeb A, et al.
Support Care Cancer
. 2015 Oct;
24(4):1857-63.
PMID: 26454864
Purpose: Although considered safer than central venous catheters for administration of cancer chemotherapy, totally implanted venous access (TIVA) is associated with adverse events that may impair prognosis and quality of...